— Multitarget Approach Has Potential to Further Improve Outcomes in This Disease Characterized by Continued Unmet Need — Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) today announced the initiation of PRESERVE, a Phase 4, multicenter study investigating the combination of LUPKYNIS ® and belim...